Steven M Bair MD
Clinical Fellow in Hematology/Oncology at the Hospital of the University of Pennsylvania
Join to View Full Profile
1665 Aurora CtAurora, CO 80045
Phone+1 720-848-0000
Fax+1 720-848-1786
Dr. Bair is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of PennsylvaniaMSCE, Clinical Epidemiology, 2018 - 2020
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2017 - 2020- University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2017
Case Western Reserve University School of MedicineClass of 2014
Certifications & Licensure
CO State Medical License 2020 - 2025
WY State Medical License 2021 - 2025
PA State Medical License 2014 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- The Myron F. Kanter and Lawrence J. Kanter Endowment Award (Cardiology) Case Western Reserve University School of Medicine, 2014
- Alpha Omega Alpha Inductee Alpha Omega Alpha, 2014
Publications & Presentations
PubMed
- 1 citationsLoncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
Haematologica. 2025-03-01 - DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.Jessica Allen, Diana Abbott, Joy Eskandar, Steven M Bair, Bradley Haverkos
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-01 - Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.Meryl Colton, Enkhtsetseg Purev, Bradley Haverkos, Steven Bair, Jagar Jasem
Clinical Lymphoma, Myeloma & Leukemia. 2024-11-01
Abstracts/Posters
- Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell LymphomasSteven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Steven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
The Utility of FDG-PET in the Treatment of Hodgkin LymphomaNovember 6th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
